蓝舌病毒HbC3株S7基因5’非编码区序列分析

根据已发表的蓝舌病毒(bluetongue virus．BTV)10型标准株S7基因设计合成一对与其5'-NCR(noncoding region)序列同源的引物．经反转录-聚合酶链反应(RT-PCR)扩增出HbC3株和10型标准株长度分别为277bp和290bp的S7基因5’非编码区cDNA片段．以建立起dsRNA体外扩增系统．将扩增的BTV-HbC3毒株的S7基因5’非编码区片段通过粘端连接克隆到pUCm-T载体中．用PCR技术和限制性内切酶分析鉴定，表明获得重组质粒pUCm-T-BTV-HbC3-S7．通过核苷酸序列分析方法分别将2个毒株的S7基因5’非编码区与呼肠孤病毒-3(reovirus-3)型比对。发现BTV-HbC3株与呼肠孤病毒-3 L2基因5’非编码区基因具有完全的同源性．将BTV-HbC3毒株接种在不同细胞系如猴肾传代细胞(Vero)、人肝癌细胞(Hep-3B)和小鼠成纤维细胞(L929)等细胞株上，比较BTV-HbC3在不同种系细胞上的增殖特征，并且用双向免疫扩散试验证实BTV-HbC3和BTV-10型之间的血清学关系．结合本实验室的研究结果提示BTV-HbC3株可能是蓝舌病毒的一个新的基因型．     

Ln7O6（BO3）（PO4）2：Eu（Ln=Al,Gd,Y）的UVU—UV激发和辐射发光

本文报道了Ln7O6(BO3)(PO4)2:Eu(Ln=La,Gd,Y)在UVU－UV区的激发光谱及Eu^3 在可见区的发射光谱,其激发光谱包括基质在真空紫外区的激发带和激活剂离子在紫外区的Eu^3 -O^2-电荷迁移带,随着La^3 ,Gd^3 ,Y^3 离子半径逐渐减小,Eu^3 -O^2-电荷迁移带的重心位置逐渐向高能量方向移动,Gd7O6(BO3)(PO4)2:Eu和Y7O6（BO3）（PO4）2：Eu在真空紫外区的吸收与Eu^3 -O^2-电荷迁移带位于紫外区的吸收的比值要高于在La7O6(BO3)(PO4)2:Eu中的这个比值,激发能可被基质吸收,传递给激活剂离子,得到Eu^3 的红光发射,在Gd7O6(BO3)(PO4)2:Eu中,^5D0→^7F1的发射强度较强,在Y7O6（BO3）（PO4）2：Eu中,^5D0→^7F2和^5D0→^7F3的跃迁较强。     

7-羟基喹啉-(H2O)n(n=1,2)复合物氢键相互作用的密度泛函理论研究

许多生理过程都通过分子间相互作用来实现。氢键则是最基本的化学作用力之一。具有碱性和酸性双官能团的芳香族化合物能与水作用形成氢键网络,对于实现生物体系的物质转移（质子转移、离子转移）起着十分重要的作用。在非水溶剂中,通过氢键发生质子转移反应动力学实验特征也己进行了广泛的研究。本文用密度泛函B3LYP方法在6-311G^＊基组水平上对7-羟基喹啉-水复合物相互作用进行了研究,从成键特征及氢键复合物的稳定关系方面进行了理论计算。     

Design and Synthesis of Some New Furan-Based Derivatives and Evaluation of In Vitro Cytotoxic Activity

New furan-based derivatives have been, designed, synthesized, and evaluated for their cytotoxic and tubulin polymerization inhibitory activities. DNA flow cytometric study of pyridine carbohydrazide 4 and N-phenyl triazinone 7 demonstrated G₂/M phase cell cycle disruptions. Accumulation of cells in the pre-G1 phase and positive annexin V/PI staining, which may be caused by degeneration or fragmentation of the genetic components, suggested that cell death occurs via an apoptotic cascade. Furthermore, compounds 4 and 7 had a strong pro-apoptotic impact through inducing the intrinsic mitochondrial mechanism of apoptosis. This mechanistic route was verified by an ELISA experiment that indicated a considerable rise in the levels of p53 and Bax and a drop in the level of Bcl-2 when compared with the control.     

具有非对称中心结构的硼酸盐Bi2ZnB2O7的合成、晶体结构和光学性质

具有非对称中心结构的硼酸盐Bi2ZnB2O7由固相反应法在低于700℃下制备得到.X射线单晶结构分析表明,该化合物以正交空间群Pba2结晶,晶体学参数为:a=1.0819(2)nm,b=1.1023(2)nm,c=0.4890(1)nm,Z=4.其晶体结构中包含分别由[BO3]3-和[BO4]5-组成的[B2O5]4-和[B2O7]8-基团,它们被[ZnO4]四面体通过共用O原子的方式连接成二维2∞[ZnB2O7]6-层,这些层由Bi3+离子进一步结合形成三维网.红外光谱证实了[BO3]3-和[BO4]5-基团的存在,粉末倍频效应测试表明,其强度为KDP(KH2PO4)的4倍,UV漫反射光谱表明该物质吸收边约为360 nm.     

P2X7 Receptors in Astrocytes: A Switch for Ischemic Tolerance

A sub-lethal ischemic episode (preconditioning [PC]) protects neurons against a subsequent lethal ischemic injury. This phenomenon is known as ischemic tolerance. PC itself does not cause brain damage, but affects glial responses, especially astrocytes, and transforms them into an ischemia-resistant phenotype. P2X7 receptors (P2X7Rs) in astrocytes play essential roles in PC. Although P2X7Rs trigger inflammatory and toxic responses, PC-induced P2X7Rs in astrocytes function as a switch to protect the brain against ischemia. In this review, we focus on P2X7Rs and summarize recent developments on how astrocytes control P2X7Rs and what molecular mechanisms they use to induce ischemic tolerance.     

Synthesis and Anti-Neuroinflammatory Activity of 1,7-diphenyl-1,4-heptadien-3-ones in LPS-Stimulated BV2 Microglia Via Inhibiting NF-κB/MAPK Signaling Pathways

A series of 1,7-diphenyl-1,4-heptadien-3-ones with various substituents (HO-, CH₃O-, CH₃-, Cl-) on the phenyl rings were synthesized and evaluated for anti-neuroinflammatory effects in LPS-stimulated BV2 microglia. The pharmacological results showed that the target compounds bearing methoxy groups greatly inhibited LPS-induced NO release, and that the active compounds CU-19 and CU-21 reduced the level of NO, TNF-α, IL-6 and PGE-2, downregulated the expression of COX-2 and iNOS in LPS-stimulated BV2 cells. A study of the mechanism of action revealed that CU-19 and CU-21 inhibited the nuclear translocation of NF-κB and phosphorylation of MAPKs (ERK, JNK, and p38). A preliminary pharmacokinetic study in rats revealed that the pharmacokinetic properties of CU-19 and CU-21 were dramatically ameliorated in comparison with the pharmacokinetic properties of curcumin.     

Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment

The purpose of this study was to evaluate the potential of a newly modified cyclodextrin derivative, water-soluble β-cyclodextrin–epichlorohydrin (β-CD), as an effective drug carrier to enhance the poor solubility and bioavailability of galangin (GAL), a poorly water-soluble model drug. In this regard, inclusion complexes of GAL/β-CDP were prepared. UV-VIS spectrophotometry, Fourier-transform infrared spectroscopy (FTIR), X-ray crystallography (XRD), zeta potential analysis, particle size analysis, field emission scanning electron microscopy (FESEM), and transmission electron microscopy (TEM) were applied to characterize the synthesized GAL/β-CD. Michigan Cancer Foundation-7 (MCF-7; human breast cancer cells) and rat embryo fibroblast (REF; normal cells) were employed to examine the in vitro cytotoxic effects of GAL/β-CD using various parameters. The dye-based tests of MTT and crystal violet clearly exhibited that GAL/β-CD-treated cells had a reduced proliferation rate, an influence that was not found in the normal cell line. The cells’ death was found to follow apoptotic mechanisms, as revealed by the dye-based test of acridine orange/ethidium bromide (AO/EtBr), with the involvement of the mitochondria via caspase-3-mediated events, as manifested by the Rh 123 test. We also included a mouse model to examine possible in vivo toxic effects of GAL/β-CD. It appears that the inclusion complex does not have a significant influence on normal cells, as indicated by serum levels of kidney and liver enzymatic markers, as well as thymic and splenic mass indices. A similar conclusion was reached on the histological level, as manifested by the absence of pathological alterations in the liver, kidney, thymus, spleen, heart, and lung.     

In Silico Drug Repurposing of FDA-Approved Drugs Highlighting Promacta as a Potential Inhibitor of H7N9 Influenza Virus

Influenza virus infections continue to be a significant and recurrent public health problem. Although vaccine efficacy varies, regular immunisation is the most effective method for suppressing the influenza virus. Antiviral drugs are available for influenza, although two of the four FDA-approved antiviral treatments have resulted in significant drug resistance. Therefore, new treatments are being sought to reduce the burden of flu-related illness. The time-consuming development of treatments for new and re-emerging diseases such as influenza and the high failure rate are increasing concerns. In this context, we used an in silico-based drug repurposing method to repurpose FDA-approved drugs as potential therapies against the H7N9 virus. To find potential inhibitors, a total of 2568 drugs were screened. Promacta, tucatinib, and lurasidone were identified as promising hits in the DrugBank database. According to the calculations of MM-GBSA, tucatinib (−54.11 kcal/mol) and Promacta (−56.20 kcal/mol) occupied the active site of neuraminidase with a higher binding affinity than the standard drug peramivir (−49.09 kcal/mol). Molecular dynamics (MD) simulation studies showed that the C-α atom backbones of the complexes of tucatinib and Promacta neuraminidase were stable throughout the simulation period. According to ADME analysis, the hit compounds have a high gastrointestinal absorption (GI) and do not exhibit properties that allow them to cross the blood–brain barrier (BBB). According to the in silico toxicity prediction, Promacta is not cardiotoxic, while lurasidone and tucatinib show only weak inhibition. Therefore, we propose to test these compounds experimentally against the influenza H7N9 virus. The investigation and validation of these potential H7N9 inhibitors would be beneficial in order to bring these compounds into clinical settings.     

CaLaAl3O7:Eu3+的凝胶-燃烧法合成及其发光性能

采用柠檬酸凝胶-燃烧法合成了CaLa1-xAl3O7:xEu3+(0.05≤x≤0.8)材料的前驱粉末,在低于700℃退火处理时,得到非晶态样品,而高于800℃退火处理后为纯相的CaLa1-xAl3O7:xEu3+粉末样品.通过激发光谱和发射光谱研究了Eu3+在CaLaAl3O7基质中的发光性能及Eu3+掺杂量,退火温度和柠檬酸与金属离子的配比等对发光强度的影响.结果显示,非晶态和晶态CaLa1-xAl3O7:xEu3+样品均可发光,非晶态样品的最强激发峰出现在7F0-5D2的465 nm处,而晶相样品的最强激发峰为7F0-5L6跃迁的394nm.非晶态粉末在465 nm激发下发射光谱由5D0-7F0的578 nm和5D0-7F1的587 nm及5D0-7F2的615nm组成.而晶态粉末在394 nm激发下的发射光谱与非晶态相比5D0-7F0跃迁消失了,同时5D0-7F1跃迁发生谱线劈裂,出现在587和596 nm两处.随着退火温度的升高,主峰615 nm强度增强了,但5D0-7F1跃迁峰的增强更加明显.